The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
Abstract
OBJECTIVE: To determine an effective and tolerable dose of a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, MK-0974, for the acute treatment of migraine. METHODS: Randomized, double-blind, parallel-group, clinical trial with a two-stage, adaptive, dose-ranging design. Patients were allocated to treat a moderate or severe migraine attack with MK-0974 (25, 50, 100, 200, 300, 400, or 600 mg), rizatriptan 10 mg, or placebo taken orally. The primary endpoint was pain relief (reduction to mild or none) 2 hours after dosing. Secondary endpoints included pain freedom at 2 hours and sustained pain relief at 24 hours. A prespecified, blinded, automated interim analysis was used to discontinue randomization to less effective doses. RESULTS: Per the adaptive study design, the four lowest MK-0974 groups (25, 50, 100, 200 mg) were discontinued due to insufficient efficacy. For the remaining treatment groups, the estimated pain relief proportions at 2 hours were 300 mg (n = 38) 68.1%, 400 mg (n = 45) 48.2%, 600 mg (n = 40) 67.5%, rizatriptan 10 mg (n = 34) 69.5%, and placebo (n = 115) 46.3%. The prespecified primary efficacy hypothesis test, which compared the average 2-hour pain relief response proportion of the combined 300, 400, and 600 mg MK-0974 groups to placebo, was significant (P = 0.015). A generally similar efficacy pattern was seen for other endpoints. MK-0974 was generally well tolerated and there did not appear to be an increase in adverse events with increasing dose. CONCLUSIONS: The novel, orally administered calcitonin gene-related peptide (CGRP) receptor antagonist, MK-0974, was effective and generally well tolerated for the acute treatment of migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olesen, J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2003.00824.x · Cited by 2,056
Cited by
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Diencephalic and brainstem mechanisms in migraine
Akerman, S., Holland, P. R., & Goadsby, P. J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3057 · Cited by 532
The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache
OLESEN, J. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.003 · Cited by 296
Kadmiel, M., Fritz-Six, K., Pacharne, S., Richards, G. O., Li, M., Skerry, T. M., & Caron, K. M. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0400 · Cited by 44
Van der Schueren, B. J., Lunnon, M. W., Laurijssens, B. E., Guillard, F., Palmer, J., Van Hecken, A., Depré, M., Vanmolkot, F. H., & de Hoon, J. N. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008329548 · Cited by 39
Metadata
- Authors
- Ho, T. W., Mannix, L. K., Fan, X., Assaid, C., Furtek, C., Jones, C. J., Lines, C. R., & Rapoport, A. M.
- Venue
- Neurology
- Published
- 2008-04-15
- Volume
- 70
- Issue
- 16
- Pages
- 1304-1312
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2098988727
- Cited by
- 464
- References
- 1
- FWCI
- 33.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. https://app.cochat.ai/papers/10.1212/01.wnl.0000286940.29755.61
- The paper
- Ho, T. W., Mannix, L. K., Fan, X., Assaid, C., Furtek, C., Jones, C. J., Lines, C. R., & Rapoport, A. M. (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. https://doi.org/10.1212/01.wnl.0000286940.29755.61
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.